心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

无症状糖尿病患者冠状动脉疾病的风险分层和筛查：法国心血管学会和法国糖尿病学会立场文件

2021-11-01 法国心血管学会 Diabetes Metab . 2021 Mar;47(2):101185.

糖尿病

无症状糖尿病患者冠状动脉疾病的风险分层和筛查：法国心血管学会和法语糖尿病学会立场文件

中文标题：

无症状糖尿病患者冠状动脉疾病的风险分层和筛查：法国心血管学会和法国糖尿病学会立场文件

英文标题：

Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology

发布机构：

法国心血管学会

发布日期：

2021-11-01

简要介绍：

无症状糖尿病患者冠状动脉疾病的风险分层和筛查：法国心血管学会和法语糖尿病学会立场文件

相关资料下载：
[AttachmentFileName(sort=1, fileName=1.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b82ce1c002255588, title=无症状糖尿病患者冠状动脉疾病的风险分层和筛查：法国心血管学会和法国糖尿病学会立场文件 , enTitle=Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology, guiderFrom=Diabetes Metab . 2021 Mar;47(2):101185., authorId=0, author=, summary=无症状糖尿病患者冠状动脉疾病的风险分层和筛查：法国心血管学会和法语糖尿病学会立场文件, cover=https://img.medsci.cn/20211214/1639463852251_1614372.png, journalId=0, articlesId=null, associationId=643, associationName=法国心血管学会, associationIntro=null, copyright=0, guiderPublishedTime=Mon Nov 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>无症状糖尿病患者冠状动脉疾病的风险分层和筛查：法国心血管学会和法语糖尿病学会立场文件</p>, tagList=[TagDto(tagId=216, tagName=糖尿病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=95307, appHits=101, showAppHits=0, pcHits=344, showPcHits=95206, likes=0, shares=10, comments=3, approvalStatus=1, publishedTime=Tue Nov 16 23:56:36 CST 2021, publishedTimeString=2021-11-01, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=小小医者, createdTime=Fri Nov 05 14:23:04 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Fri Jan 05 05:34:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=1.pdf)])
1.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1185451, encodeId=f3b01185451ff, content=👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:38:55 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074193, encodeId=9d9e10e41936b, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:08:30 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067299, encodeId=5310106e299a1, content=码, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0885585216, createdName=时期, createdTime=Fri Nov 05 15:10:34 CST 2021, time=2021-11-05, status=1, ipAttribution=)]
    2022-01-18 ms6000000807686529

    👍👍👍

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1185451, encodeId=f3b01185451ff, content=👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:38:55 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074193, encodeId=9d9e10e41936b, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:08:30 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067299, encodeId=5310106e299a1, content=码, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0885585216, createdName=时期, createdTime=Fri Nov 05 15:10:34 CST 2021, time=2021-11-05, status=1, ipAttribution=)]
    2021-11-26 H8888888

    不错 学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1185451, encodeId=f3b01185451ff, content=👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:38:55 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074193, encodeId=9d9e10e41936b, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:08:30 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067299, encodeId=5310106e299a1, content=码, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0885585216, createdName=时期, createdTime=Fri Nov 05 15:10:34 CST 2021, time=2021-11-05, status=1, ipAttribution=)]
    2021-11-05 时期

    码

    0

相关指南

欧洲心脏病学会/心力衰竭协会关于新型降糖药物在心力衰竭患者中的作用和安全性的立场文件

欧洲心脏病学会(ESC,European Society of Cardiology) · 2021-11-04

糖尿病微循环障碍临床用药专家共识(2021年版)

中国微循环学会糖尿病与微循环专业委员会 · 2021-04-20

2021 JBDS-IP指南：糖尿病患者择期和急诊手术的围术期管理

英国糖尿病协会联合住院治疗组(JBDS-IP,Joint British Diabetes Societiesfor Inpatient Care Group) · 2021-03-10

2021 KDA临床实践指南：糖尿病

韩国糖尿病协会(KDA,Korean Diabetes Association) · 2021-07-15

2021 国际专家共识建议：临床实践中糖尿病感觉运动多神经病的筛查，诊断和管理

国外内分泌相关专家小组（统称） · 2021-09-18

中国老年糖尿病诊疗指南(2021年版)

中华医学会老年医学分会 · 2021-01-29